Latest Regulatory Milestones News

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Dome Gold Mines has announced a $5 million Share Purchase Plan at a 6.25% discount to fund critical milestones for its Sigatoka Sands Project in Fiji, aiming to secure a mining licence and commence operations.

Platinum Asia Investments Limited has finalized its special dividend payment, confirming an amount of AUD 0.2011 per share with a high franking percentage. The dividend is set for payment in September following court approval of its scheme of arrangement.

American West Metals has completed critical development and permitting milestones at its Storm Copper Project in Nunavut, Canada, advancing its Pre-Feasibility Study and revealing promising drilling results that hint at resource expansion.

Diatreme Resources has achieved a significant regulatory milestone with Project Status granted across its silica sand tenements in Far North Queensland, alongside critical tenure renewals that preserve its strategic landholdings. This development strengthens its pathway toward long-term production of low-iron, high-purity silica sand.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Star Minerals Limited will have its trading suspension lifted on 19 August 2025 following the release of important assay results and its response to an ASX Price Query.

Challenger Gold’s Argentinian subsidiary has obtained the crucial explosives permit to begin drill and blast operations for toll milling at the Hualilan Gold Project, unlocking near-term cash flow potential. The company’s recent Pre-Feasibility Study underscores robust economics, setting the stage for accelerated development.